Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 16/20 | 0.41 |
| ▸ | RARB | P10826 | 3/20 | 0.35 |
| ▸ | RARG | P13631 | 3/20 | 0.35 |
| ▸ | RARA | P10276 | 2/20 | 0.35 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.33 |
| ▸ | RXRB | P28702 | 4/20 | 0.32 |
| ▸ | RXRG | P48443 | 3/20 | 0.32 |
| ▸ | GNRHR | P30968 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16731567 | 0.87 | RXRA (0.40) | RXRARARBRARGRARACYP26A1 | |
| SCHEMBL14376650 | 0.84 | RXRA (0.46) | RXRARARBRARGRARACYP26A1 | |
| SCHEMBL6678059 | 0.80 | RXRA (0.49) | RXRARARBRARGRARACYP26A1 | |
| SCHEMBL7931914 | 0.80 | RXRA (0.49) | RXRARARBRARGRARACYP26A1 | |
| SCHEMBL4666392 | 0.78 | RXRA (0.43) | RXRARARBRARGRARACYP26A1 | |
| SCHEMBL4669400 | 0.78 | RXRA (0.37) | RXRARARBRARGRARACYP26A1 | |
| SCHEMBL6678267 | 0.77 | RXRA (0.43) | RXRARARBRARGRARACYP26A1 | |
| SCHEMBL4666920 | 0.77 | RXRA (0.39) | RXRARARBRARGRARACYP26A1 | |
| SCHEMBL4668400 | 0.75 | RXRA (0.35) | RXRARARBRARGRARACYP26A1 | |
| SCHEMBL4666466 | 0.74 | RXRA (0.38) | RXRARARBRARGRARARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535640-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2022-12-27 | — | — | US | disclosed |
| EP-3658564-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2021-05-19 | — | — | EP | disclosed |
| US-20200207794-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2020-07-02 | — | — | US | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090275598-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2008030618-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN ING. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN ING. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN ING. (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2007033002-A1 | CONFORMATIONALLY CONSTRAINED 3- (4-HYDROXY-PHENYL) - SUBSTITUTED-PROPANOIC ACIDS USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007033002-A1 | CONFORMATIONALLY CONSTRAINED 3- (4-HYDROXY-PHENYL) - SUBSTITUTED-PROPANOIC ACIDS USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-03-22 | — | — | WO | disclosed |
| US-6777418-B2 | FOR TREATING OR PREVENTING EMPHYSEMA, CANCER AND DERMATOLOGICAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-08-17 | — | — | US | disclosed |
| EP-1324970-A2 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-09 | — | — | EP | disclosed |
| US-20020082265-A1 | For treating or preventing emphysema, cancer and dermatological disorders | SYNTEX (U.S.A.) LLC | 2002-06-27 | — | — | US | disclosed |
| WO-2002028810-A2 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082265-A1 | For treating or preventing emphysema, cancer and dermatological disorders | RXRA, RXRG, RXRB | RXRA 1/4885RARB 6/4885RARG 4/4885 |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | PC, PNLIP, PDHX | RXRA 218/4885RARB 2342/4885RARG 1676/4885 |
| US-20200207794-A1 | METAL COMPLEXES | IMMT, MCU, SOD1 | RXRA 3459/4885RARB 3700/4885RARG 3228/4885 |
| US-20090275598-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | PC, PNLIP, PDHX | RXRA 218/4885RARB 2342/4885RARG 1676/4885 |
| US-11535640-B2 | Metal complexes | IMMT, MCU, SOD1 | RXRA 3459/4885RARB 3700/4885RARG 3228/4885 |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | GOT2, GLS2, PC | RXRA 150/4885RARB 899/4885RARG 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.